The impact of hyperuricemia on in-hospital mortality and incidence of acute kidney injury in patients undergoing percutaneous coronary intervention

Circulation Journal

Volumn 75, Issue 3, 2011, Pages 692-697

  Park, Sang Ho ^a   Shin, Won Yong ^a   Lee, Eun Young ^a   Gil, Hyo Wook ^a   Lee, Se Whan ^a   Lee, Seung Jin ^a   Jin, Dong Kyu ^a   Hong, Sae Yong ^a  

^a Soonchunhyang University   (South Korea)

Author keywords

Ischemic heart disease; Kidney; Percutaneous coronary intervention; Renal failure

Indexed keywords

ALBUMIN; C REACTIVE PROTEIN; CREATININE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN; HEMOGLOBIN A1C; NITROGEN; UREA; URIC ACID;

ACUTE KIDNEY FAILURE; ADULT; AGED; ANEMIA; ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIET RESTRICTION; DISEASE ASSOCIATION; FEMALE; GLOMERULUS FILTRATION RATE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMATOCRIT; HEMODIALYSIS; HUMAN; HYPERURICEMIA; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PERCUTANEOUS CORONARY INTERVENTION; PREDICTION; RETROSPECTIVE STUDY;

ACUTE KIDNEY INJURY; AGED; ANGIOPLASTY, BALLOON, CORONARY; CORONARY ARTERY DISEASE; CREATININE; DIABETES COMPLICATIONS; FEMALE; GLOMERULAR FILTRATION RATE; HOSPITAL MORTALITY; HUMANS; HYPERURICEMIA; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; RETROSPECTIVE STUDIES; RISK FACTORS; URIC ACID;

EID: 79952330121     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-10-0631     Document Type: Article

References (40)

1. Le Feuvre C, Dambrin G, Helft G, Tabet S, Beygui F, Legendre C, et al. Comparison of clinical outcome following coronary stenting or balloon angioplasty in dialysis versus non-dialysis patients. Am J Cardiol 2000; 85: 1365-1368.
2. Ting HH, Tahirkheli NK, Berger PB, McCarthy JT, Timimi FK, Mathew V, et al. Evaluation of long-term survival after successful percutaneous coronary intervention among patients with chronic renal failure. Am J Cardiol 2001; 87: 630-633.
3. Mccullough PA, Wolyn R, Rocher LL, Levin RN, O'Neill WW. Acute renal failure after coronary intervention: Incidence, risk factors, and relationship to mortality. Am J Med 1997; 103: 368-375.
4. Rihal CS, Textor SC, Grill DE, Berger PB, Ting HH, Best PJ, et al. Incidence and prognostic importance of acute renal failure after percutaneous coronary intervention. Circulation 2002; 105: 2259-2264.
5. Gruberg L, Weissman NJ, Pichard AD, Waksman R, Kent KM, Satler LF, et al. Impact of renal function on morbidity and mortality after percutaneous aortocoronary saphenous vein graft intervention. Am Heart J 2003; 145: 529-534.
6. Parfrey PS, Griffiths SM, Barrett BJ, Paul MD, Genge M, Withers J, et al. Contrast material induced renal failure in patients with diabetes mellitus, renal insufficiency, or both: A prospective controlled study. N Engl J Med 1989; 320: 143-149.
7. Rich MW, Crecelius CA. Incidence, risk factors, and clinical course of acute renal insufficiency after cardiac catheterization in patients 70 years of age or older: A prospective study. Arch Intern Med 1990; 150: 1237-1242.
8. Albert SG, Shapiro MJ, Brown WW, Goodgold H, Zuckerman D, Durham R, et al. Analysis of radiocontrast-induced nephropathy by dual-labeled radionuclide clearance. Invest Radiol 1994; 29: 618-623.
9. Best PJ, Lennon R, Ting HH, Bell MR, Rihal CS, Holmes DR, et al. The impact of renal insufficiency on clinical outcomes in patients undergoing percutaneous coronary interventions. J Am Coll Cardiol 2002; 39: 1113-1119.
10. Toprak O, Cirit M, Yesil M, Byrne DW, Postaci N, Bayata S, et al. Metabolic syndrome as a risk factor for contrast-induced nephropathy in non-diabetic elderly patients with renal impairment. Kidney Blood Press Res 2006; 29: 2-9.
11. Iakovou I, Dangas G, Mehran R, Lansky AJ, Ashby DT, Fahy M, et al. Impact of gender on the incidence and outcome of contrastinduced nephropathy after percutaneous coronary intervention. J Invasive Cardiol 2003; 15: 18-22.
12. Khanal S, Attallah N, Smith DE, Kline-Rogers E, Share D, O'Donnell MJ, et al. Statin therapy reduces contrast-induced nephropathy: An analysis of contemporary percutaneous interventions. Am J Med 2005; 118: 843-849.
13. Cirit M, Toprak O, Yesil M, Kline-Rogers E, Share D, O'Donnell MJ, et al. Angiotensin-converting enzyme inhibitors as a risk factor for contrast-induced nephropathy. Nephron Clin Pract 2006; 104: c20-c27.
14. Toprak O, Cirit M, Esi E, Postaci N, Yesil M, Bayata S, et al. Hyperuricemia as a risk factor for contrast-induced nephropathy in patients with chronic kidney disease. Catheter Cardiovasc Interv 2006; 67: 227-235.
15. Dangas G, Iakovou I, Nikolsky E, Aymong ED, Mintz GS, Kipshidze NN, et al. Contrast-induced nephropathy after percutaneous coronary interventions in relation to chronic kidney disease and hemodynamic variables. Am J Cardiol 2005; 95: 13-19.
16. Nikolsky E, Mehran R, Lasic Z, Mintz GS, Lansky AJ, Na Y, et al. Low hematocrit predicts contrast-induced nephropathy after percutaneous coronary interventions. Kidney Int 2005; 67: 706-713.
17. Feig DI, Kang DH, Johnson RJ. Uric acid and cardiovascular risk. N Engl J Med 2008; 359: 1811-1821.
18. Short RA, Johnson RJ, Tuttle KR. Uric acid, microalbuminuria and cardiovascular events in high-risk patients. Am J Nephrol 2005; 25: 36-44.
19. Kang DH, Nakagawa T. Uric acid and chronic renal disease: Possible implication of hyperuricemia on progression of renal disease. Semin Nephrol 2005; 25: 43-49.
20. Madsen TE, Muhlestein JB, Carlquist JF, Horne BD, Bair TL, Jackson JD, et al. Serum uric acid independently predicts mortality in patients with significant, angiographically defined coronary disease. Am J Nephrol 2005; 25: 45-49.
21. Dincer HE, Dincer AP, Levinson DJ. Asymptomatic hyperuricemia: to treat or not to treat. Cleve Clin J Med 2002; 69: 594-608.
22. Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH, et al. Uric acid and the state of the intrarenal reninangiotensin system in humans. Kidney Int 2004; 66: 1465-1470.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Terkeltaub R. Crystal deposition disease. In: Goldman L, Ausiello D, editors. Cecil' Textbook of medicine, 22nd edn. Philadelphia: Saunders, 2004; 1702-1710.
25. Schwab SJ, Hlatky MA, Pieper KS, Davidson CJ, Morris KG, Skelton TN, et al. Contrast nephrotoxicity: A randomized controlled trial of a nonionic and an ionic radiographic contrast agent. N Engl J Med 1989; 320: 149-153.
26. Rudnick MR, Goldfarb S, Wexler L, Ludbrook PA, Murphy MJ, Halpern EF, et al. Nephrotoxicity of ionic and nonionic contrast media in 1196 patients: A randomized trial: The Iohexol Cooperative Study. Kidney Int 1995; 47: 254-261.
27. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus. Kidney Int 1994; 45: 259-265.
28. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997; 29: 465-477.
29. Bakris GL, Lass N, Gaber AO, Jones JD, Burnett JC Jr. Radiocontrast medium-induced declines in renal function: A role for oxygen free radicals. Am J Physiol 1990; 258: F115-F120.
30. Yoshioka T, Fogo A, Beckman JK. Reduced activity of antioxidant enzymes underlies contrast media-induced renal injury in volume depletion. Kidney Int 1992; 41: 1008-1015.
31. Brady HR, Singer GG. Acute renal failure. Lancet 1995; 346: 1533-1540.
32. Pannu N, Wiebe N, Tonelli M. Prophylaxis strategies for contrastinduced nephropathy. JAMA 2006; 295: 2765-2779.
33. Hongo M, Hidaka H, Sakaguchi S, Nakanishi K, Ichikawa M, Hirota N, et al. Association between serum uric acid levels and cardiometabolic risk factors among Japanese junior high school students. Circ J 2010; 74: 1570-1577.
34. Ejaz AA, Mu W, Kang DH, Roncal C, Sautin YY, Henderson G, et al. Could uric acid have a role in acute renal failure? Clin J Am Soc Nephrol 2007; 2: 16-21.
35. Persson PB, Hansell P, Liss P. Pathophysiology of contrast mediuminduced nephropathy. Kidney Int 2005; 68: 14-22.
36. Detrenis S, Meschi M, Musini S, Savazzi G. Lights and shadows on the pathogenesis of contrast-induced nephropathy: State of the art. Nephrol Dial Transplant 2005; 20: 1542-1550.
37. Okura T, Higaki J, Kurata M, Irita J, Miyoshi K, Yamazaki T, et al. Elevated serum uric acid is an independent predictor for cardiovascular events in patients with severe coronary artery stenosis: Subanalysis of the Japanese Coronary Artery Disease (JCAD) Study. Circ J 2009; 73: 885-891.
38. Mehran R, Aymong ED, Nikolsky E, Lasic Z, Iakovou I, Fahy M, et al. A simple risk score for prediction of contrast-induced nephropathy after percutaneous coronary intervention: Development and initial validation. J Am Coll Cardiol 2004; 44: 1393-1399.
39. George J, Carr E, Davies J, Belch JJ, Struthers A. High-dose allopurinol improves endothelial function by profoundly reducing vascular oxidative stress and not by lowering uric acid. Circulation 2006; 114: 2508-2516.
40. Waring WS, McKnight JA, Webb DJ, Maxwell SR. Lowering serum urate does not improve endothelial function in patients with type 2 diabetes. Diabetologia 2007; 50: 2572-2579.